| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of Bisabolone oxide A is α-glucosidase, an enzyme that catalyzes the hydrolysis of terminal α-1,4-linked glucose residues. The compound is an inhibitor of this enzyme. It also inhibits α-glucokinase. By inhibiting α-glucosidase, Bisabolone oxide A may modulate carbohydrate digestion and glucose absorption.
|
|---|---|
| ln Vitro |
In vitro, Bisabolone oxide A inhibits α-glucosidase activity. The compound has also been shown to inhibit α-glucokinase. It reduces neuronal excitability. These data suggest that Bisabolone oxide A is a multi-target compound with potential applications in diabetes and neurological research.
|
| ln Vivo |
In vivo, Bisabolone oxide A has been shown to exhibit biotoxicity in Helicoverpa armigera, Aedes vittatus, and Anopheles subpictus larvae. This suggests potential insecticidal activity. The compound's inhibition of α-glucosidase could also have implications for glucose metabolism in vivo. However, detailed in vivo studies on its efficacy and safety are limited.
|
| Enzyme Assay |
The in vitro enzyme assay for Bisabolone oxide A involves measuring its inhibitory activity against α-glucosidase. The enzyme is incubated with a chromogenic substrate, such as 4-nitrophenyl-α-D-glucopyranoside, in the presence of the compound. The release of 4-nitrophenol is measured spectrophotometrically at 400 nm. The IC50 value is calculated by fitting dose-response curves to the inhibition data. The compound's inhibition of α-glucokinase can be measured using similar enzymatic assays.
|
| Cell Assay |
Cellular assays for Bisabolone oxide A may involve the use of neuronal cell lines to assess its effects on excitability. Cells are treated with the compound, and neuronal activity is measured using electrophysiological techniques or calcium imaging. The compound's effects on cell viability and metabolic activity may also be assessed. However, specific cellular assay protocols for this compound are not detailed in the available literature.
|
| Animal Protocol |
In vivo animal studies for Bisabolone oxide A have been conducted in insect larvae, including Helicoverpa armigera, Aedes vittatus, and Anopheles subpictus. The compound was tested for biotoxicity in these larvae. Studies in rodent models of diabetes or neurological disorders would be needed to further characterize its therapeutic potential.
|
| ADME/Pharmacokinetics |
As a terpenoid, the pharmacokinetic properties of Bisabolone oxide A would depend on its physicochemical characteristics. The compound has a molecular weight of 236.35 g/mol and a molecular formula of C15H24O2. It is likely to be lipophilic and may have good oral bioavailability. Detailed ADME parameters such as half-life, bioavailability, and tissue distribution are not available in the public domain. The compound is typically stored under standard laboratory conditions.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for Bisabolone oxide A in mammals in the available literature. The compound has shown biotoxicity in insect larvae. As a research chemical, it is intended for laboratory use only and should be handled with standard safety precautions. Toxicity studies would be required if the compound were to be developed further for therapeutic applications.
|
| References | |
| Additional Infomation |
It has been reported that chamomile (Matricaria chamomilla) contains [S-(R,R)]-dihydro-2,2,6-trimethyl-6-(4-methyl-3-cyclohexen-1-yl)-2H-pyran-3(4H)-one, and related data have been published. See also: ... View more ...
Bisabolone oxide A (CAS#: 22567-38-0) is a terpenoid compound isolated from Matricaria chamomilla L. It has a molecular formula of C15H24O2 and a molecular weight of 236.35. Bisabolone oxide A is an α-glucosidase inhibitor. It reduces neuronal excitability. The compound has been shown to inhibit α-glucokinase and exhibit biotoxicity in insect larvae. |
| Molecular Formula |
C15H24O2
|
|---|---|
| Molecular Weight |
236.35
|
| Exact Mass |
236.178
|
| CAS # |
22567-38-0
|
| PubChem CID |
91700388
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.649
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
354
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O1C(C)(C)C(CCC1(C)C1CC=C(C)CC1)=O
|
| InChi Key |
MJWZYBQLHJQQJJ-DOMZBBRYSA-N
|
| InChi Code |
InChI=1S/C15H24O2/c1-11-5-7-12(8-6-11)15(4)10-9-13(16)14(2,3)17-15/h5,12H,6-10H2,1-4H3/t12-,15+/m1/s1
|
| Chemical Name |
(6S)-2,2,6-trimethyl-6-[(1S)-4-methylcyclohex-3-en-1-yl]oxan-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2310 mL | 21.1551 mL | 42.3101 mL | |
| 5 mM | 0.8462 mL | 4.2310 mL | 8.4620 mL | |
| 10 mM | 0.4231 mL | 2.1155 mL | 4.2310 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
